STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.

Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap "Open original source" above to read their full reporting and support the contributing newsroom directly.